Literature DB >> 11461070

Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.

J F Thompson1, G A Siebert, Y G Anissimov, B M Smithers, A Doubrovsky, C D Anderson, M S Roberts.   

Abstract

This study sought to use a microdialysis technique to relate clinical and biochemical responses to the time course of melphalan concentrations in the subcutaneous interstitial space and in tumour tissue (melanoma, malignant fibrous histiocytoma, Merkel cell tumour and osteosarcoma) in patients undergoing regional chemotherapy by Isolated Limb Infusion (ILI). 19 patients undergoing ILI for treatment of various limb malignancies were monitored for intra-operative melphalan concentrations in plasma and, using microdialysis, in subcutaneous and tumour tissues. Peak and mean concentrations of melphalan were significantly higher in plasma than in subcutaneous or tumour microdialysate. There was no significant difference between drug peak and mean concentrations in interstitial and tumour tissue, indicating that there was no preferential uptake of melphalan into the tumours. The time course of melphalan in the microdialysate could be described by a pharmacokinetic model which assumed melphalan distributed from the plasma into the interstitial space. The model also accounted for the vascular dispersion of melphalan in the limb. Tumour response in the whole group to treatment was partial response: 53.8% (n = 7); complete response: 33.3% (n = 5); no response: 6.7% (n = 1). There was a significant association between tumour response and melphalan concentrations measured over time in subcutaneous microdialysate (P< 0.01). No significant relationship existed between the severity of toxic reactions in the limb or peak plasma creatine phosphokinase levels and peak melphalan microdialysate or plasma concentrations. It is concluded that microdialysis is a technique well suited for measuring concentrations of cytotoxic drug during ILI. The possibility of predicting actual concentrations of cytotoxic drug in the limb during ILI using our model opens an opportunity for improved drug dose calculation. The combination of predicting tissue concentrations and monitoring in microdialysate of subcutaneous tissue could help optimise ILI with regard to post-operative limb morbidity and tumour response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461070      PMCID: PMC2364039          DOI: 10.1054/bjoc.2001.1902

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?

Authors:  Z Y Wu; B M Smithers; C Anderson; M S Roberts
Journal:  Melanoma Res       Date:  2000-02       Impact factor: 3.599

2.  Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit.

Authors:  O CREECH; E T KREMENTZ; R F RYAN; J N WINBLAD
Journal:  Ann Surg       Date:  1958-10       Impact factor: 12.969

3.  Models of hepatic elimination: comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity, and systemic recycling on hepatic elimination.

Authors:  M S Roberts; J D Donaldson; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1988-02

4.  Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma.

Authors:  B C Vrouenraets; B B Kroon; J M Klaase; O E Nieweg; G W van Slooten; J A van Dongen
Journal:  Melanoma Res       Date:  1995-12       Impact factor: 3.599

5.  Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations.

Authors:  E M Landaw; J J DiStefano
Journal:  Am J Physiol       Date:  1984-05

6.  Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion.

Authors:  R N Scott; R Blackie; D J Kerr; J Hughes; G Burnside; R M MacKie; D S Byrne; A J McKay
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

Review 7.  Microdialysis--principles and applications for studies in animals and man.

Authors:  U Ungerstedt
Journal:  J Intern Med       Date:  1991-10       Impact factor: 8.989

8.  VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha.

Authors:  N Renard; P T Nooijen; L Schalkwijk; R M De Waal; A M Eggermont; D Liénard; B B Kroon; F J Lejeune; D J Ruiter
Journal:  J Pathol       Date:  1995-07       Impact factor: 7.996

9.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions.

Authors:  J Wieberdink; C Benckhuysen; R P Braat; E A van Slooten; G A Olthuis
Journal:  Eur J Cancer Clin Oncol       Date:  1982-10

10.  Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.

Authors:  J M Klaase; B B Kroon; J H Beijnen; G W van Slooten; J A van Dongen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

View more
  9 in total

Review 1.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors:  Christian Joukhadar; Markus Müller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol).

Authors:  William J Bodell; Alexander P Bodell; Donald D Giannini
Journal:  Neuro Oncol       Date:  2006-10-03       Impact factor: 12.300

Review 3.  Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development.

Authors:  Jaishri Blakeley; Jana Portnow
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10-23       Impact factor: 4.481

Review 4.  Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Authors:  Dale Han; Georgia M Beasley; Douglas S Tyler; Jonathan S Zager
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-10-07       Impact factor: 4.481

5.  A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion.

Authors:  Georgia M Beasley; Ketan Sharma; Joyce Wong; Mike Miller; Ryan S Turley; Michael Lidsky; Melanie Masoud; Mark W Dewhirst; Paul J Mosca; Jonathan S Zager; Douglas S Tyler
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

6.  Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma.

Authors:  Sara Cecchini; Donatella Sarti; Stefano Ricci; Ludovico Delle Vergini; Manuela Sallei; Stefano Serresi; Giuseppe Ricotti; Luca Mulazzani; Fabrizia Lattanzio; Giammaria Fiorentini
Journal:  World J Clin Oncol       Date:  2015-08-10

Review 7.  Drug structure-transport relationships.

Authors:  Michael S Roberts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-24       Impact factor: 2.745

Review 8.  Molecular Aspects of the Isolated Limb Infusion Procedure.

Authors:  Jüri Teras; Michael J Carr; Jonathan S Zager; Hidde M Kroon
Journal:  Biomedicines       Date:  2021-02-07

Review 9.  Revolutionizing Therapeutic Drug Monitoring with the Use of Interstitial Fluid and Microneedles Technology.

Authors:  Tony K L Kiang; Sahan A Ranamukhaarachchi; Mary H H Ensom
Journal:  Pharmaceutics       Date:  2017-10-11       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.